Repurposing crizotinib to target RIPK1-dependent cell death

Receptor-interacting protein kinase 1 (RIPK1) has emerged as a key regulator of cell death and inflammation, which are implicated in the pathogenesis of many inflammatory and degenerative diseases. RIPK1 is therefore a putative therapeutic target in many of these diseases. However, no pharmacological inhibitor of RIPK1-mediated cell death is currently in clinical use. Recognizing that a repurposed drug has an expedited clinical development pipeline, here we performed a high-throughput drug screen of Food and Drug Administration (FDA)-approved compounds and identified a novel use for crizotinib as an inhibitor of RIPK1-dependent cell death. Furthermore, crizotinib rescued TNF-alpha-induced death in mice with systemic inflammatory response syndrome. RIPK1 kinase activity was directly inhibited by crizotinib. These findings identify a new use for an established compound and are expected to accelerate drug development for RIPK1-spectrum disorders.

Automated summary

A high-throughput drug screen of FDA-approved compounds revealed that crizotinib can be used as an inhibitor of RIPK1-dependent cell death. Crizotinib directly inhibits RIPK1 kinase activity and rescues TNF-alpha-induced death in mice with systemic inflammatory response syndrome. These findings are expected to accelerate drug development for RIPK1-spectrum disorders.